Morgan Stanley resumed coverage of Kymera Therapeutics with a rating of Overweight and set a new price target of $70.00

Morgan Stanley upgraded Kymera Therapeutics from Equal-Weight to Overweight and set a new price target of $79.00

B. Riley Securities upgraded Kymera Therapeutics from Neutral to Buy and set a new price target of $60.00

BofA Securities upgraded Kymera Therapeutics from Neutral to Buy and set a new price target of $51.00

Stifel resumed coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $55.00

Citigroup initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $52.00

BTIG Research initiated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $60.00

BMO Capital Markets initiated coverage of Kymera Therapeutics with a rating of Market Perform and set a new price target of $55.00

Wells Fargo upgraded Kymera Therapeutics from Equal Weight to Overweight and set a new price target of $57.00

Stephens initiated coverage of Kymera Therapeutics with a rating of Overweight and set a new price target of $65.00

4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

SCHEDULE 13D/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)

8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)

424B5 - Kymera Therapeutics, Inc. (0001815442) (Filer)

424B5 - Kymera Therapeutics, Inc. (0001815442) (Filer)

8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)

8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)

144 - Kymera Therapeutics, Inc. (0001815442) (Subject)

144 - Kymera Therapeutics, Inc. (0001815442) (Subject)

144 - Kymera Therapeutics, Inc. (0001815442) (Subject)

4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 5,044,500 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 655,500 shares of common stock in the offering. The shares of common stock are being sold at a public offering pr

WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares

Sanofi to advance Kymera's next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety profile Kymera is eligible for up to $975 million in collaboration milestones, double digit royalties,and may opt-in to 50/50 development and profit share of KT-485 in the U.S. WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced an update to its IRAK4 partn

Gilead Sciences, Inc. (NASDAQ:GILD) and Kymera Therapeutics, Inc. (NASDAQ:KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential including in breast cancer and other solid tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625261668/en/ CDK2-directed MGDs are a new type of drug designed to remove CDK2 – a key contributor in tumor growth – rather than just inhibiting its function. Traditional inhibitors o

Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in blood achieved at all doses above 1.5 mg Complete STAT6 degradation achieved in both blood and skin at all MAD doses ≥50 mg KT-621 impact on Th2 biomarkers in line or superior to dupilumab with median TARC reduction up to 37% and median Eotaxin-3 reduction up to 63% KT-621 was well-tolerated with a safety profile undifferentiated from placebo, with no serious adverse events, no severe adverse events, no treatment related adverse events in more than one subject

WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-621 in healthy volunteers on Monday, June 2, 2025. The Company will host a video webcast at 8:00 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast and copy of the presentation will be a

WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:  Jefferies Global Healthcare Conference in New York, NY on June 5 at 8:10 a.m. ET;Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL on June 10 at 3:20 p.m. ET; andWolfe Research Virtual Biotech Day on June 26, one-on-one meetings only. Live webcasts of the presentations will be available under "News and Events" in the Investors sectio

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression KT-621 Phase 1 healthy volunteer SAD/MAD trial completed with data to be reported in June 2025 KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) ongoing with data expected in 4Q25 Two parallel Phase 2b trials in AD and asthma planned to start in 4Q25 and 1Q26, respectively WATERTOWN, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for

IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activity comparable or superior to approved and clinically active drugs in multiple efficacy animal models of lupus and RA IND-enabling studies are ongoing with Phase 1 testing expected to

Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, with broad clinical potential in rheumatic and other autoimmune diseases, expected to enter Phase 1 clinical trial in early 2026 KT-474/SAR444656 (IRAK4) Phase 2b trials in HS and AD ongoing, led by partner Sanofi; Kymera achieved a $20 million milestone payment as part of the IRAK4 collaboration in April 2025 Strategic decision made not to advance KT-295 (TYK2) into further clini

WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-621 in healthy volunteers on Monday, June 2, 2025. The Company will host a video webcast at 8:00 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast and copy of the presentation will be a

IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activity comparable or superior to approved and clinically active drugs in multiple efficacy animal models of lupus and RA IND-enabling studies are ongoing with Phase 1 testing expected to

Watertown, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it will host a video webcast from 10:00 a.m. to 11:30 a.m. ET on Friday, May 9, 2025. The company will report first quarter 2025 financial results and also disclose its new oral development candidate targeting a high value undrugged target for multiple autoimmune and rheumatic diseases. Additionally, the Company will review highlights and upcoming milestones across its industry-leading immunology pipeline. To join the video call or view the li

WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Mr. Goodman brings a wealth of diverse experience in the life sciences industry to Kymera and will lead business development strategy and activities for the company. "We continue to stay focused on our mission of building a fully integrated biopharmaceutical company focused on discovering and developing oral drugs with biologics-like activity," said Nello Mainolfi, Ph.D., Founder,

Company's focus on advancing first-in-class oral degraders with biologics-like activity to address areas of significant patient need and market potential STAT6 oral degrader KT-621, with dupilumab-like activity, expected to enter Phase 1 clinical trial in the second half of 2024 TYK2 oral degrader KT-294, with a TYK2 loss-of-function profile and expected biologics-like activity, planned to enter Phase 1 clinical trial in the first half of 2025 IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data expected in the first half of 2025 Company to hold virtual Immunology R&D Day webcast today at

WATERTOWN, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared webcast information for the virtual Immunology R&D Day that the Company will host on January 4, 2024, from 10:00 a.m. to 12:00 p.m. ET. The R&D Day will focus on the Company's emerging pipeline of high-value immunology programs, including new target disclosures, supporting preclinical data and timing to clinical study initiation. To join the webcast, please visit this link, or the "Events and Presentations" page of the Investors section on the Company'

WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer. Dr. Chadwick joins Kymera with extensive experience overseeing global development operations, regulatory and program management at a range of biopharmaceutical companies. As a member of the Company's senior management team, Dr. Chadwick will develop and execute near-term and long-range strategies to maximize the impact of Kymera's expanding pipeline. "At Kymera, we ha

WATERTOWN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Ellen Chiniara, J.D., as Chief Legal Officer and Corporate Secretary. Ms. Chiniara joins Kymera with extensive experience overseeing legal activities at biopharmaceutical companies ranging from the discovery phase through commercialization. Ms. Chiniara will lead Kymera's legal, governance, and intellectual property functions as a member of the Company's senior management team. "We continue to scale rapidly and broade

WATERTOWN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Victor Sandor, M.D.C.M., to its Board of Directors. Dr. Sandor joins Kymera's Board as a senior executive with deep expertise in global biopharmaceutical clinical development. Kymera also announced that Don Nicholson, PhD, who has served on Kymera's Board of Directors for the past five years, will retire from his position. "At this stage of Kymera's evolution, we will greatly benefit from Victor's experience building develo

Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience WINSTON-SALEM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (NASDAQ:PROK) ("ProKidney" or the "Company"), a leading clinical-stage cellular therapeutics company focused on therapies for chronic kidney disease ("CKD"), today announced the appointments of John M. Maraganore, Ph.D. and Jennifer Fox to its Board of Directors. "We are thrilled to welcome John and Jen to the ProKidney Board. They each have a wealth of experience t

Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in blood achieved at all doses above 1.5 mg Complete STAT6 degradation achieved in both blood and skin at all MAD doses ≥50 mg KT-621 impact on Th2 biomarkers in line or superior to dupilumab with median TARC reduction up to 37% and median Eotaxin-3 reduction up to 63% KT-621 was well-tolerated with a safety profile undifferentiated from placebo, with no serious adverse events, no severe adverse events, no treatment related adverse events in more than one subject

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression KT-621 Phase 1 healthy volunteer SAD/MAD trial completed with data to be reported in June 2025 KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) ongoing with data expected in 4Q25 Two parallel Phase 2b trials in AD and asthma planned to start in 4Q25 and 1Q26, respectively WATERTOWN, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for

Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, with broad clinical potential in rheumatic and other autoimmune diseases, expected to enter Phase 1 clinical trial in early 2026 KT-474/SAR444656 (IRAK4) Phase 2b trials in HS and AD ongoing, led by partner Sanofi; Kymera achieved a $20 million milestone payment as part of the IRAK4 collaboration in April 2025 Strategic decision made not to advance KT-295 (TYK2) into further clini

KT-621 (STAT6) Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025 KT-621 Phase 1b trial in atopic dermatitis (AD) patients expected to initiate in 2Q25 with data in 4Q25, followed by two parallel Phase 2b trials in AD and asthma starting in 4Q25 and 1Q26, respectively KT-295 (TYK2) Phase 1 trial is expected to start in 2Q25, with data expected in 4Q25 KT-474/SAR444656 (IRAK4) Phase 2b trials in hidradenitis suppurativa (HS) and AD ongoing, led by partner Sanofi, with primary completion of both trials expected by mid-2026 New oral degrader program against a high-value immunology target to be announced in early May 2025 in a company webcast Well-capitali

WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines with biologics-like activity for immunological diseases, will report fourth quarter and full year 2024 financial results on February 27, 2025. The Company will host a new video conference call format at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Ky

KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to dose ranging Phase 2b studies to accelerate overall development timelines; completion of both expanded trials expected by mid-2026 KT-295, a new TYK2 degrader, selected as the development candidate to advance into Phase 1 clinical trial in the first half of 2025, in line with prior program guidance Company to shift focus and resources from oncology to its expanding immunology pipeline, and will only advance KT-333 (STAT3) and KT-253 (MDM2) beyond Phase 1 with a partner Well-ca

WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report third quarter 2024 financial results on October 31, 2024, and will host a conference call at 8:30 a.m. ET. To access the October 31 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast of the Company's conference call will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the web

Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following interim analysis of safety and efficacy data STAT6 degrader program on track to initiate Phase 1 in second half of 2024 with data in first half of 2025; TYK2 degrader program on track to initiate and complete Phase 1 in 2025 Data from KT-253 (MDM2) and KT-333 (STAT3) oncology degrader programs presented at ASCO and EHA, with major responses in liquid and solid tumors; Phase 1a dose escalation studies expected to complete enrollment in second half of 2024 Well-capitalized with $702 million in cash as of June 30, 2024, and runway into the first half of 2

Watertown, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report second quarter 2024 financial results on August 7, 2024, and will host a conference call at 8:30 a.m. ET. To access the August 7 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast of the Company's conference call will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the we

KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2) expected to start Phase 1 in the first half of 2025, both with Phase 1 data in 2025 KT-253 (MDM2) and KT-333 (STAT3) Phase 1 dose escalation studies ongoing with clinical data updates at ASCO and EHA, respectively Well-capitalized with $745 million in cash as of March 31, 2024, and runway into the first half of 2027 Company to hold call and webcast today at 8:30 a.m. ET WATERTOWN, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmac

SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

SC 13G - Kymera Therapeutics, Inc. (0001815442) (Subject)

SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

SC 13D/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

SC 13D - Kymera Therapeutics, Inc. (0001815442) (Subject)

SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)